sdbn.org

OCEANSIDE, Calif.--(BUSINESS WIRE)--International Stem Cell Corporation (OTCBB: ISCO), www.internationalstemcell.com, announced today that ISCO's Research and Therapeutic Development Group, together with a group of scientists from the University of California, Irvine (UCI), is starting a second phase of essential pre-clinical experiments to test retinal pigment epithelium derived from parthenogenetic... More...

SAN DIEGO--(BUSINESS WIRE)--Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX), a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced financial results for the fourth quarter... More...

SAN DIEGO, March 18, 2010 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the Barclays Capital 2010 Global Healthcare Conference on Tuesday, March 23, 2010, at 5:15 p.m. Eastern Time (2:15 p.m. Pacific Time) at the Loews Miami Beach Hotel in Miami, Florida. Cindy McGee, Arena's Manager of Investor Relations and Corporate... More...

San Diego-based Sequenom (NASDAQ: SQNM) is entering a critical phase in its management of the corporate crisis that erupted in its laboratories last year. It’s stepping back into the...

[[Click headline to continue reading.]] More...

Who was it that once said ‘if at first you don’t succeed, try, try again?’ This Friday, San Diego-based Somaxon expects find out from the FDA whether its persistence has paid off,...

[[Click headline to continue reading.]] More...

LOS ANGELES--(BUSINESS WIRE)--Abraxis BioScience, Inc. (NASDAQ:ABII - News) today announced that its randomized registrational Phase 3 clinical trial comparing ABRAXANE (protein-bound paclitaxel) with Taxol (paclitaxel) injection, both in combination with carboplatin, met the studys primary endpoint by demonstrating that ABRAXANE showed a significant improvement in overall response rate as compared... More...

SAN DIEGO, March 16 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. today announced that the underwriter of its recently completed public offering of common stock has exercised in full its option to purchase an additional 1,365,000 shares of common stock to cover over-allotments. The sale of the additional shares closed on March 16, 2010. When taking into account the sale of the... More...

SAN DIEGO, March 16 /PRNewswire-FirstCall/ -- Cardium Therapeutics today reported highlights and financial results for its fourth quarter and fiscal year ended December 31, 2009, and other important recent developments and outlook for 2010.

(Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO)

Highlights of 2009 and Recent Developments

More...

SAN DIEGO, March 17 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced the execution of a research collaboration and license agreement with Bayer Schering Pharma AG, Germany, a worldwide leading specialty pharmaceutical company. The collaboration partners Prometheus' proprietary oncology diagnostic platform with Bayer's broad oncology pipeline... More...

SAN DIEGO, March 17 /PRNewswire/ -- Zogenix, Inc. ("Zogenix"), a privately held pharmaceutical company, announced that it has initiated a pivotal Phase 3 clinical trial with ZX002, a novel, oral, controlled-release formulation of hydrocodone without acetaminophen. ZX002 is being developed for the treatment of moderate to severe pain in individuals who require around-the-clock opioid therapy... More...